Does TECLISTAMAB-CQYV Cause Hepatotoxicity? 6 Reports in FDA Database
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
According to the FDA Adverse Event Reporting System (FAERS), 6 reports of Hepatotoxicity have been filed in association with TECLISTAMAB-CQYV. This represents 0.4% of all adverse event reports for TECLISTAMAB-CQYV.
6
Reports of Hepatotoxicity with TECLISTAMAB-CQYV
0.4%
of all TECLISTAMAB-CQYV reports
3
Deaths
3
Hospitalizations
How Dangerous Is Hepatotoxicity From TECLISTAMAB-CQYV?
Of the 6 reports, 3 (50.0%) resulted in death, 3 (50.0%) required hospitalization.
Is Hepatotoxicity Listed in the Official Label?
This adverse event is not currently listed in the official FDA drug label for TECLISTAMAB-CQYV. However, 6 reports have been filed with the FAERS database.
What Other Side Effects Does TECLISTAMAB-CQYV Cause?
Cytokine release syndrome (406)
Immune effector cell-associated neurotoxicity syndrome (153)
Off label use (122)
Death (116)
Plasma cell myeloma (96)
Infection (83)
Neutropenia (74)
Fatigue (72)
Pyrexia (67)
Covid-19 (64)
What Other Drugs Cause Hepatotoxicity?
METHOTREXATE (1,917)
ACETAMINOPHEN (1,557)
LEFLUNOMIDE (829)
HYDROXYCHLOROQUINE (715)
PREDNISONE (707)
RITUXIMAB (702)
ETANERCEPT (699)
ADALIMUMAB (674)
CYCLOPHOSPHAMIDE (632)
SULFASALAZINE (613)
Which TECLISTAMAB-CQYV Alternatives Have Lower Hepatotoxicity Risk?
TECLISTAMAB-CQYV vs TEDIZOLID
TECLISTAMAB-CQYV vs TEDUGLUTIDE
TECLISTAMAB-CQYV vs TEDUGLUTIDE\WATER
TECLISTAMAB-CQYV vs TEGAFUR
TECLISTAMAB-CQYV vs TEGAFUR\URACIL